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Antibodies to malondialdehyde (MDA)-modified macromolecules (adducts) have been detected in the
serum of patients with atherosclerosis and correlate with the progression of this disease. However, the
epitope and its formation have not been characterized. Studies have shown that excess MDA can be degraded
to acetaldehyde, which combines with proteins to from a stable dihydropyridine adduct. To investigate, mice
were immunized with MDA adducts in the absence of adjuvant and showed an increase in antibodies to MDA
adducts and the carrier protein as the concentration of MDA was increased. In fact, a number of the
commercially available antibodies to MDA-modified proteins were able to be inhibited by a chemical
analogue, hexyl-MAA. Also, MDA–MAA adducts were detected in the serum and aortic tissue of JCR diabetic/
atherosclerotic rats. These studies determined that commercially available antibodies to MDA predominantly
react with the MAA adduct and are present in the JCR model of atherosclerosis in both the serum and the
aortic tissue. Therefore, the immune response to MDA-modified proteins is most probably to the
dihydropyridine structure (predominant epitope in MAA), which suggests that MAA adducts may play a
role in the development and/or progression of atherosclerosis.
© 2010 Elsevier Inc. All rights reserved.
Studies have shown that MDA1 is formed as a result of lipid
peroxidation [1] and is capable of binding to various macromolecules
[2,3]. Modification of proteins/lipoproteins has been associated with
the development and/or progression of atherosclerotic disease [4,5].
Indeed, these modified proteins/lipoproteins have been found in the
circulation [6,7] and atherosclerotic lesions [8–10] of patients with
atherosclerotic disease. Within atherosclerotic lesions, a “protein
quality disease” develops as the result of protein unfolding and
modification of protein and/or macromolecular complex function at
the cellular level [10]. Additionally, modified lipoproteins have been
proven to be immunogenic, generating autoantibodies against
epitopes within the apolipoprotein B-100 component [11].
The ability of these modified molecules to be highly immunogenic
and proinflammatory poses a large threat to the vessel tissue if they
are not removed, thereby drastically increasing the pathological
processes involved in the development and/or progression of
atherosclerosis [12].
Additionally the initiation of antibody responses toMDAadducts has
been used in the past as amarker of atherosclerosis [6,13–15]. However,
the exact epitope of antibody binding and the role of this adduct in the
pathogenesis of this disease remain relatively unknown. It has been
demonstrated thatMDA can break down to form acetaldehyde (AA) [1],
andour grouphas shown thatAA in thepresenceofMDA formsaunique
malondialdehyde–acetaldehyde adduct we have termed MAA [16].
Important to this disease process is the observation that this adduct can
initiate proinflammatory, profibrotic, and immune responses in the
absence of adjuvant, resulting in the production of T cell and
autoantibody responses [2,3,17].
More recently, MAA adducts have proven to be highly immuno-
genic in the absence of adjuvants [18]; they can bind scavenger
receptors and elicit both proinflammatory and T-cell responses
[19,20]. However, most important is the ability of the MAA adduct
to generate antibody responses to the carrier protein, providing a
potential mechanism by which tolerance to self proteins is abrogated,
resulting in autoimmunity [21]. A concept that has been under
investigation involves the lipid peroxidation of membranes to form
MDA. This by-product can combine with proteins to modify lysine
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residues and formMDA adducts, one of which is the highly stable and
biologically relevant MAA adduct [22].
There are a number of risk factors that predict the development
and/or progression of atherosclerosis, including age, gender, obesity,
hypertension, diabetes mellitus, serum cholesterol, and smoking,
which increase the oxidative state [15]. Taking into account the
number of aldehydes generated from smoking (AA from the cigarette
itself) and the oxidative stress detected in obese patients with
diabetes, a strong possibility exists for an increased presence of both
MDA and AA in these patients, which may result in the formation of
MAA adducts and the resultant protein quality disease [10]. Therefore,
it was the purpose of this study to begin examining the relationship
between MDA and MAA adducts and the potential role of adducts in
the development and/or progression of atherosclerosis.
Materials and methods
Animals
Balb/c mice were purchased from the National Cancer Institute and
maintained on a Purina rat chow diet. Male JCR (leptin receptor−/−)
obese diabetic atherosclerotic rats were purchased from Charles Rivers
Laboratories (Wilmington,MA,USA) and kept on a high-cholesterol diet
for 6–8 months. Animals were allowed free access to their food and
water up to 1 h before sacrifice. All procedures were approved by the
Animal Subcommittee of the University of Nebraska Medical Center
(UNMC; JCR rats) or Omaha VA Medical Center (Balb/c mice) in
accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals.
Chemicals and proteins
Bovine serum albumin (Alb) and rat serum albumin (RSA) were
purchased from Calbiochem (La Jolla, CA, USA). AA was obtained from
Aldrich Chemical Co. (Milwaukee, WI, USA). MDAwas obtained as the
sodium salt (MDA–Na) by treatment of tetramethoxypropane
(Aldrich Chemical Co.) with NaOH, according to the method of
Iwata and Kikugawa [23]. Phytic acid (PA) and diethylenetriamine-
pentaacetic acid (DTPA) were obtained from Sigma Chemical Co. (St.
Louis, MO, USA).
Preparation of modified proteins
Alb or RSA and low-density lipoprotein (LDL) were adjusted to
2 mg andmodified by reacting with increasing concentrations of MDA
in the presence or absence of 1.0 mM AA in 0.1 M phosphate buffer,
pH 7.2, containing 2 mM DTPA and 2 mM PA, at 37 °C for 3 days,
followed by dialysis against three changes of 0.1 M sodium phosphate
buffer for 24 h at 4 °C [16]. MAA-modified albumin was checked for
modification by the amount of fluorescent MAA adduct present
(excitation 398 nm and emission 460 nm) using a Turner Biosystems
(Sunnyvale, CA, USA) LS-5B spectrofluorimeter.
Comparison of anti-MDA and MAA antibodies
The specificity of the monoclonal and polyclonal anti-MAA
antibodies [24] in conjunction with other commercially available
anti-MDA antibodies (mouse 1F83 anti-MDA, Abcam, Cambridge, MA,
USA; goat anti-MDA,Meridian Life Science, Saco, ME, USA; rabbit anti-
MDA, Calbiochem) were tested against Alb, and MAA–Alb modified at
a ratio of 2:1 (2 mM MDA:1 mM AA), or increasing concentrations of
MDA with Alb. For these experiments, 96-well Immulon IV (Nunc,
Fisher Scientific, St. Louis, MO, USA) microtiter plates were coated
with 2 μg/well Alb, Alb modified with increasing concentrations of
MDA, or MAA–Alb in bicarbonate buffer (pH 9.6) as previously
described [18]. After an overnight incubation at 37 °C, the plates were
washed three times with phosphate-buffered saline containing 0.05%
Tween 20 (PBST), and the MDA antibodies were diluted as determined
by themanufacturer's directions and incubated at 37 °C for 45 min.MAA
antibodies were diluted 1:1000 for the monoclonal and 1:2000 for the
polyclonal. Plateswerewashed in PBSTand a secondary antibody (HRP–
rabbit anti-mouse IgG, HRP–goat anti-rabbit IgG, or HRP–rabbit anti-
goat IgG; Sigma Chemical Co.) was added and incubated at 37 °C for
45 min. The plates were washed and TMB substrate was added. Color
changes were monitored by an MRX II microplate reader (Dynatech,
Chantilly, VA, USA) at 450 nm. Standard curves were established using
known concentrations of the appropriate mouse, goat, or rabbit IgG
(Sigma Chemical Co.), and the concentrations of unknown samples
were extrapolated by using Revelations Software (Dynatech). The
means±SE of the relative concentrations of antibody from individual
mice assayed in duplicate were subtracted from the activity on the
unmodified protein and reported in nanograms per milliliter.
Competitive ELISA demonstrating specificity to the MAA epitope
Todetermine the specificity of the antibodies raised against theMAA
epitope, a competitive ELISAwas used. Briefly, ELISA plateswere coated
with MAA–Alb as described above and incubated overnight. A separate
transfer plate was used to dilute the hexyl–MAA (a synthetic analogue)
and the anti-MDA or anti-MAA antibodies. The hexyl-MAA was diluted
twofold down the plate at a starting concentration of 2000 pmol/well.
The above antibodies were added at a dilution (previously determined)
that would result in a 1.0 optical density reading on the spectropho-
tometer after 30 min of incubation. After an overnight incubation, the
plate was washed and blocked, and the contents of the transfer plate
were moved to the appropriate wells of the ELISA plate. After 1 h
incubation at room temperature, the plate was washed and the
secondary antibodies as outlined above were added for 30 min. The
absorbance was assessed as described above and the percentage
inhibition determined using the formula below were OD is the optical
density and BKG is the background:
%inhibition = ODmax–BKGð Þ− ODsample–BKG
 
= ODmax–BKGð Þ × 100:
Immunization with MDA/MAA adducts
To examine the immunogenicity of MDA and MAA adducts, Balb/c
mice were immunized with increasing concentrations of MDA-
modified Alb in the presence or absence of 1 mM acetaldehyde.
Before immunization, animals were prebled and serum tested for
background levels of anti-MAA antibodies. Modified proteins were
immunized at a concentration of 25 μg weekly for 5 weeks in the
absence of any adjuvants [18]. Following the immunization schedule,
blood was collected using retro-orbital venous puncture and serum
frozen at −20 °C until processed.
Determination of antibodies to MAA
Serum from animals immunized with MDA or MAA adducts was
screened for thepresence of anti-MAAandanti-Alb antibodies. For these
experiments plates were coated with 2:1 MAA–Alb or Alb as described
above and incubated with the antiserum at a 1:1000 dilution. After an
incubation period, a secondary HRP–rabbit anti-mouse antibody was
added. Plates were developed, absorbance was determined, and
concentrations were extrapolated as described above. Circulating anti-
MAA antibodies from prebleed serum samples prior to immunization
were subtracted from the MAA-immunized mice and reported.
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Screening of JCR rat serum for anti-MAA antibodies
Serum from Sprague–Dawley and JCR rats was collected after
6 months on a high-cholesterol diet. The JCR rat on this diet has been
used as a model of atherosclerosis as it has been shown to induce
plaque formation and mimic human disease [25]. These studies were
devised to evaluate the relevance of MDA/MAA-modified proteins
and anti-MAA/MDA antibodies in an in vivo setting. To determine
antibody concentrations, ELISA plates were coated with RSA, LDL,
oxidized LDL, MAA LDL, and aortic tissue that were unmodified or
modified with MAA as described above. A rat IgG standard was also
coated on the plate to use as a standard curve. Antiserum was
incubated at a 1:50 dilution and an HRP–rabbit anti-rat antibody used
as the secondary detecting antibody. Plates were developed and
concentrations determined as described above. To show specificity to
the MAA epitope, RSA–MAA, hexyl-MAA, aortic tissue, and aortic
tissue modified with MAA were used as inhibiting ligands. These
experiments were designed in a manner similar to the hexyl-MAA
studies described above. However, the proteins (inhibitors) were
started at 1000 μg/well and diluted twofold down the plate, the
antiserum was added at 2× concentration, and the percentage
inhibition was calculated as described above. Native Alb and RSA
(unmodified) were used as negative controls and demonstrated no
inhibitory properties of the antibody response.
Determination of MAA antigens in aortic tissue
Aortic tissues from Sprague–Dawley and JCR rats were lysed with
PBS–RIPA buffer (PBS, pH 7.4, 0.5% Triton X-100, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM Na-EDTA, and
5 μl/ml protease inhibitor cocktail; Sigma Chemical Co.) as described
previously [26]. Lysates equivalent to 50 μg were resolved under
reducing conditions by SDS–PAGE on 10% gels for detection of MAA
antigens. Lysates equivalent to 100 μg were resolved under reducing
conditions by using an 8% SDS–PAGE. Proteins were transferred to
Immuno-Blot polyvinylidene difluoridemembranes (Bio-Rad, Hercules,
CA, USA) and blocked 30 min in Odyssey blocking buffer (LiCor, Lincoln,
NE, USA) at 37 °C. Blots were incubated with anti-MAA mouse
monoclonal antibody (1:2000) dilution, followed by an IRDye-conju-
gated anti-mouse antibody (1:15,000; LiCor). Blots were scanned using
anOdyssey IR scanner (LiCor) and bandswere normalized to tubulin by
using1:4000anti-tubulinmousemonoclonal antibody(SigmaChemical
Co.) and IRDye-conjugated anti-mouse antibody as an internal control.
Datawere expressed as thedensitometric volume ofMAArelative to the
densitometric volume of tubulin for each lane.
Statistical analysis
Results are expressed as means±SEM. Statistical significance was
achieved if P values were less than 0.05. All statistical analysis was
performed using the SigmaStat (Jandel Scientific, 2002).
Results
Preliminary studies have suggested that the predominant adduct
formed when MDA combines with proteins is the MAA epitope. This
has been identified as a 1,4 dihydropyridine structure possessing
strong fluorescence properties at an excitation of 398 nm and
emission at 460 nm. Therefore, assays were performed using this
characteristic of MAA adducts to determine the amount of MAA
modification on proteins modified with various concentrations of
MDA. Table 1 shows the amount of MAA fluorescent modification
(nm/mg) on MDA-modified albumin. By fluorescence assays, MDA
alone begins to modify proteins with MAA when using as little as 0.5
to 1.0 mMMDA. At concentrations of 10 to 50 mMMDA, modification
of the protein with MDA is similar to conditions under which MAA
modification is performed using 2 mM MDA and 1 mM AA (standard
conditions). The addition of MDA to proteins at concentrations from
0.5 to 100 mM demonstrate a dose response with respect to MAA
fluorescence (0.18±0.06 to 29.20±3.36 nm/mg). The addition of
1 mM AA to the increasing concentrations of MDA showed a 5- to 10-
fold increase in MAA fluorescence. Also, measurements of the amount
of fluorescence showed that 1 mM AA increases the amount of MAA
adducts formed as the concentration of MDA is increased. Therefore,
these data show that although MDA alone will adduct protein with
the MAA epitope, other MDA adducts must also form on proteins.
To further assess whether modification of proteins with MDA
results in the modification of proteins with MAA or other MDA
adducts, increasing doses of MDA were incubated with a protein and
then examined immunologically for MDA and MAA adducts using
commercially available anti-MDA antibodies and previously reported
monoclonal (mouse × MAA) or polyclonal (rabbit × MAA) antibodies
[24]. In Table 2, the activities of a commercial monoclonal antibody to
MDA (Abcam) [3] and a monoclonal antibody prepared at UNMC [27]
to the MAA epitope are compared on proteins modified with various
concentrations of MDA (no AA added). As shown, both Abcam and
UNMC monoclonal antibodies seem to recognize similar, if not the
same, epitopes. The major difference may be in the sensitivity of the
assays as the Abcam antibody is an IgG2a and the UNMC antibody is
an IgG1.
The activity of the UNMC monoclonal antibody has been shown to
be completely inhibited by the addition of the chemical analogue for
MAA (hexyl-MAA) [28]. As shown in Fig. 1, both the UNMC and the
Abcam monoclonal antibodies demonstrated similar competitive
inhibition curves. The affinity of the two antibodies most probably
accounts for the minor differences observed. Thus, the commercially
available Abcam monoclonal antibody to MDA seems to actually be
specific for the MAA epitope.
With respect to the polyclonal antibodies tested (Table 2), the
UNMC polyclonal antibody reacted to the MDA-modified proteins in a
dose-dependent manner. More importantly, it is an affinity-purified
antibody to MAA that is completely inhibited by hexyl-MAA (Fig. 1) in
a fashion similar to the two monoclonal antibodies. These data show
that the MAA epitope is formed on proteins modified with MDA,
dependent upon the concentration of MDA used. In contrast, the two
polyclonal antibodies to MDA give variable results. Although both
react to proteins modified with MDA in a concentration-dependent
manner, two things are obvious: (1) The Calbiochem antibody reacts
at a higher level (Table 2); however, this antibody is not inhibited by
hexyl-MAA (Fig. 1). (2) The Biodesign polyclonal was inhibited by
hexyl-MAA only to 50% (Fig. 1), indicating only partial reactivity to the
MAA epitope. Interestingly, the Biodesign polyclonal is prepared by
affinity purification on an MDA-modified Sepharose column, whereas
the Calbiochem polyclonal is absorbed against protein carriers. Thus,
the differences between these antibodies may be due to the way they
were purified. These antibodies show that although the MAA epitope
is produced relative to the amount of MDA present, there are other
Table 1
Fluorescent modification of MDA- or MAA-modified albumin
Adduct (mM) MAA fluorescence (nm/mg)
MDA only MDA plus 1 mM AA
MDA 0.5 0.18±0.06 0.03±0.03
MDA 1.0 1.13±0.52 23.06±4.28
MDA 2.0 4.87±0.78 51.69±3.34
MDA 5.0 15.06±2.76 141.86±11.21
MDA 10.0 32.82±7.63 289.99±23.36
MDA 50.0 54.28±9.60 504.90±58.43
MDA 100.0 29.20±3.36 714.64±67.51
Bovine serum albumin was modified with increasing concentrations of MDA alone or
MDA with 1 mM AA (MAA) and fluorescence was assayed at 398 and 460 nm. Data are
the means±SEM of five separate experiments.
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MDA adducts that may also form. These data are supported by the
findings in Table 1 with respect to MAA fluorescence.
In an effort to determine the concentration of modified MDA that
would induce an immune response to the 2:1 MAA adduct and/or the
carrier protein, mice were immunized with increasing concentrations
of MDA as the immunogen and the serum antibody concentrations
tested for activity to Alb and Alb–MAA. Fig. 2 shows that there is a
small (not significant) antibody response up to the concentration of
5 mM, in which the animals produce antibody toMAA–Alb but little to
Alb. However, a concentration above 5 mM increases the amount of
anti-MAA antibodies in the serum of these mice. Therefore, the
predominant antibody is to MAA and not to the carrier. This remains
true as the amount of modification of albumin with MDA increased.
Mice were also injected with increasing concentrations of MDA
incubated with 1 mM AA and their sera screened for the presence of
anti-MAA antibodies. Fig. 3 shows that immunization at a ratio of as
low as 1:1 (MDA:AA) induced antibody reactivity to theMAA product.
This response increased twofold in the 2:1 immunizations and held
constant throughout the increased addition of MDA. These antibody
titers were not seen in the MDA-immunized animals until a
concentration of 10 mM was used (Fig. 2). These data show that
only a small amount of AA incubated with MDA and a protein will
cause significant antibody production to the MAA adduct, and higher
levels of MDAmost probably result in themodification of protein with
anotherMDA adduct. One other important observation is the antibody
response to the carrier protein Alb. These antibody responses were
almost half the concentration of the immunizing agent. Once the
concentration of MDA increased above 5 mM the antibody to the
carrier protein was significantly decreased, leaving only the antibody
to the MAA epitope.
Previous studies have demonstrated the presence of MAA adducts
in atherosclerotic lesions from human subject aortas [29]. Therefore,
experiments were performed to confirm the presence of antibodies to
MAA in an animal model of atherosclerosis. Serum antibody
concentrations of anti-MAA antibodies were determined using the
JCR high-cholesterol animal model of vascular injury. Fig. 4 shows the
presence of MAA antibodies in the JCR rat serum compared to the
Sprague–Dawley control rat serum. Reactivity to aortic tissue
modified with MAA and rat serum albumin MAA (modified self
proteins) was increased approximately threefold compared to the
control animals, indicating modification of a self protein in vivo. Also
increased was LDL modified with MAA and aortic tissue compared to
the Sprague–Dawley control rat serum. It is interesting to note that
JCR rats had significant reactivity to aortic tissue compared to the
control group, indicating an antibody response to self proteins.
Specificity to these antibodies was demonstrated by inhibiting these
responses with hexyl MAA (Fig. 5). Antibody reactivity was inhibited
by 60% for RSA MAA, 40% for LDL MAA, and 40% for aortic MAA,
indicating that the JCR serum had antibody to the self proteins
modified with MAA. These antibody responses could not be
completely inhibited with hexyl-MAA, indicating that part of the
response could be to the carrier protein conjugate attached to MAA or
possibly the 1:1 nonfluorescent MAA adduct. No inhibition was
demonstrated using unmodified RSA or Alb alone.
Table 2
Concentrations of antibodies to MDA adducts
Concentration
of MDA
Monoclonal antibodies Polyclonal antibodies
Abcam MS × MDA UNMC Ms × MAA Calbiochem Rb × MDA Biodesign Gt × MDA UNMC Rb × MAA
MDA 0.5 mM 2.30×105±1.60×103 0 1.39×106±3.13×105 2.75×105±1.1×104 4.05×104±1.66×103
MDA 1.0 mM 2.97×105±1.67×104 0 2.83×106±3.28×105 6.25×105±2.19×104 6.67×104±5.72×103
MDA 2.5 mM 8.53×105±5.10×104 9.67×103±1.69×102 4.46×106±4.33×105 1.25×106±4.11×105 2.47×105±5.20×104
MDA 5.0 mM 3.25×106±2.99×105 9.99×104±4.79×103 4.60×106±9.49×105 2.15×106±5.61×105 3.83×105±2.68×104
MDA 10.0 mM 3.16×106±3.48×105 7.51×105±2.76×104 6.35×106±1.35×105 3.47×106±8.41×105 5.83×105±5.31×104
MDA 50.0 mM 2.50×106±5.10×105 1.54×106±3.00×105 1.08×107±2.23×105 5.07×106±8.12×105 7.05×105±5.40×104
MDA 100.0 mM 2.75×106±4.46×105 1.48×106±3.02×105 8.13×106±1.75×105 4.57×106±6.10×105 5.80×105±5.41×104
MAA 2:1 3.10×106±1.95×105 3.10×106±1.95×105 4.76×106±9.84×105 3.52×106±6.18×105 6.94×105±3.09×104
Relative concentrations of antibodies to MDA or MAA adduct using UNMC or commercially available antibodies are shown. Albumin (Alb), Alb modified with increasing
concentrations ofMDA, andMAA–Alb (2:1) were coated on ELISA plates and incubated withmonoclonal or polyclonal antibodies toMDA/MAA adducts. Data are themeans±SEM of
five separate experiments.
Fig. 1. Competitive inhibition of anti-MAA or anti-MDA antibodies binding to MAA-
modified albumin. Anti-MAA or anti-MDA antibodies were incubated with increasing
concentrations of hexyl-MAA (chemical analogue of MAA) and used in an ELISA to assess
binding to MAA-modified albumin. Data are representative of five separate experiments.
Fig. 2. In vivo response to MDA-modified albumin. Balb/c mice were immunized with
albumin modified with increasing concentrations of MDA, and their serum was
obtained and screened against 2:1MAA-modified albumin for the presence of anti-MAA
antibodies. Data expressed are the means±SEM of five animal experiments. *P≤0.03,
significantly increased compared to Alb groups.
1483M.J. Duryee et al. / Free Radical Biology & Medicine 49 (2010) 1480–1486
To further prove the presence of MAA in the JCR model of
atherosclerosis, aortic tissue from JCR and Sprague–Dawley control
rats was excised and immunoprecipitated using the UNMC monoclo-
nal MAA antibody. Densitometry of a band at 88 kDa showed a
threefold increase in the amount of MAA-modified proteins in the JCR
aortic tissue compared to the control animal aortas (Fig. 6). These data
in conjunction with the serum antibody levels clearly indicate the
presence of both MAA-modified proteins and anti-MAA antibodies in
the JCR model of atherosclerosis.
Discussion
Modifications of proteins or lipoproteins have many deleterious
effects in a number of diseases including atherosclerosis. Plasma-
soluble-protein modifications result in their binding to scavenger
receptors, stimulating the release of proinflammatory cytokines, and
becoming immunogenic, eliciting autoantibody formation and the
generation of T cell responses [15]. The covalent binding of
acetaldehyde and malondialdehyde to proteins to form the MAA
adduct has been demonstrated to be a major player in both alcoholic
liver disease and, more recently, atherosclerosis [13,16,29]. The
formation of these modified self proteins and their biological
consequences provide a potential mechanism by which atheroscle-
rotic lesions form. Therefore, it was the purpose of this study to
evaluate the relationship of MAA modification of proteins with MDA
modification that has been reported by other investigators
[1,16,17,23,30,31].
Previous studies have demonstrated that after incubation with
MAA–albumin cultured rat heart endothelial cells up-regulate ICAM-
1, VCAM, class I, and class II molecules on their surface and increase
the release of tumor necrosis factor-α [29]. The MAA adduct in
alcoholic liver disease has proven to bind scavenger receptors on liver
sinusoidal endothelial cells, initiate T cell responses, increase the
release of proinflammatory cytokines, and initiate the fibrogenic or
wound-healing response [19,20,32,33]. This provides a possible
mechanism by which MAA-modified proteins or lipoproteins bind
scavenger receptors on the surface of endothelial cells of the aorta,
increase cell surface markers of inflammation, and initiate macro-
phage migration into the intimal space. Binding to these scavenger
receptors could overload the cells shunting the modified protein into
the intima. As well, if dysfunctional protein clearance for these
Fig. 3. In vivo response to MDA-modified albumin in the presence of 1 mM AA. Balb/c
mice were immunized with Alb modified with 1 mM AA and increasing concentrations
of MDA and their sera were screened against 2:1 MAA-modified albumin for the
presence of anti-MAA antibodies. Data expressed are the means±SEM of five animal
experiments. *P≤0.029, significantly increased compared to Alb groups. #P ≤ 0.03,
significantly decreased compared to Alb in the 2:1 immunized mice.
Fig. 4. Serum antibody concentrations toMAA-modified proteins in JCR rats. JCR rats were
fedahigh-cholesterol diet for 6–8 months. Serumwas assayed for thepresenceof antibody
to MAA using aortic tissue, aortic tissue modified with MAA, rat serum albumin modified
with MAA, and LDL modified with MAA. Results are expressed in ng/ml of rat IgG using a
standard curve. Data are expressed as the means±SEM of six animal experiments.
*P≤0.004, significantly increased compared to Sprague control serum. #P ≤ 0.001,
significantly different comparing aorta to aorta MAA coating antigens.
Fig. 5. Competitive inhibition of anti-MAA or aortic serum antibodies in JCR rats. Serum
from JCR rats was incubated with increasing concentrations of hexyl-MAA and then
incubatedwith corresponding antigen to look for inhibition binding to the epitope. Data
are representative of three animal experiments.
Fig. 6. Immunoprecipitation of MAA in aortic tissue from JCR rats. Aortic tissue from JCR
or Sprague–Dawley rats was collected and immunoprecipitated using a monoclonal
anti-MAA antibody. Presented data are of an 88-kDa band expressed as the means±SEM
of three animal experiments. *P=0.005, significantly different from Sprague control rats.
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adducts is impaired (i.e., protein chaperones and the ubiquitin–
proteasome pathway) and/or the modification of cellular membrane
proteins is greater than clearance, then the buildup of dysfunctional
proteins may result in disease. The resultant accumulation of
dysfunctional proteins and protein aggregates (i.e., atherosclerotic
amyloid) is hypothesized to play a critical role in vascular disease
progression [10].
MDA-modified proteins or lipoproteins have long been thought to
play an active role in the onset and/or progression of atherosclerosis
[6,15]. The formation of these MDA adducts has been attributed to the
breakdown of unsaturated fatty acids or lipid peroxidation reacting
with lysine on proteins. Lipid peroxidation occurs when cells are
exposed to reactive oxygen species causing cell walls to rupture and
membrane lipids to degrade to the end-product malondialdehyde [6].
It has been shown that malondialdehyde is able to spontaneously
break down and form acetaldehyde [1]. We hypothesize that if only a
small concentration of acetaldehyde is present with malondialdehyde
and a protein, then the stable adduct MAA can be formed as has
previously been demonstrated. This is evident as demonstrated by the
data above showing that MAA modification is present with as little as
0.5 mM MDA in the presence of AA. Many, if not all, anti-MDA
antibodies are generated using 10 mM MDA [1,34–36]. In our hands,
although mice immunized with 10 mM MDA produced less antibody
than mice immunized with MAA (2:1, MDA:AA) ratio, antibody was
detected. Also, these data prove that just a small amount of AA can
cause MDA to react with proteins to form the MAA adduct and
subsequently antibody formation takes place. Some of the commercial
antibodies could not be completely inhibited with hexyl-MAA, the
synthetic analogue, which mimics the 4-methyl-1,4-dihydropyridine-
3,5-dicarbaldehyde derivative of lysine. One potential reason for this
incomplete inhibition would be that some of these antibodies
recognize the 1:1 linear MAA adduct that forms when excess AA is
present in the reaction [16,24,28,37]. This could explain why when
the level of MDA is increased (which can break down to form AA) the
antibody response to MAA is decreased.
One question that arises is how these two chemicals (AA and
MDA) are present at the same time in the body to make these
modified self proteins. MDA from lipid peroxidation could be
attributed to the high-fat diet people consume every day, especially
as increased fatty liver (alcoholic or nonalcoholic) and the incidence
of atherosclerosis are on the rise. AA could come from the breakdown
of MDA to AA or the oxidation of alcohol from drinking [38],
fermentation of food in the gut [39], metabolism of threonine by
threonine aldolase in rodents only [40,41], and smoking [42]. In fact,
cigarette smoke extract has been shown to react with MDA and
proteins to make MAA-modified proteins [43]. Given the highly
oxidative state of smoking, it has been shown that oxidative stress
increases the amount of lipid peroxidation in the lungs, which
increases the plasma and tissue levels of MDA [44–46]. Importantly,
this could be one potential mechanism of how cigarette smoking may
be a cofactor and increase the risk of cardiovascular disease.
In conclusion, commercially available antibodies to MDA were
shown to predominantly react with the MAA adduct. Thus, these data
suggest that many of these commercially available antibodies have
specificity for the dihydropyridine structure, as confirmed by
inhibition studies using an analogue to MAA. MAA-modified proteins
induce immune responses at physiological modifications better than
MDA alone. Proteins modified with MAA are present in the JCR rat
model of atherosclerosis in both the serum and the aortic tissue.
Modification of carrier proteins with MAA provides a potential
mechanism by which self proteins are modified and recognized by
the immune system. Therefore, the immune response to MDA-
modified proteins is most probably to the dihydropyridine structure
(predominant epitope in MAA) and suggests that MAA adducts may
play a role in the development and/or progression of vascular disease
such as atherosclerosis.
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